Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF(Tumor Necrosis Factor)Therapy

TerminatedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions
Ulcerative Colitis
Interventions
DRUG

Vedolizumab

standard vedolizumab induction (300mg IV at week 0, 2, 6)

Trial Locations (2)

94305

Stanford University, Stanford

N6A5A5

University of Western Ontario, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

University of Western Ontario, Canada

OTHER

collaborator

University of California, San Diego

OTHER

lead

Stanford University

OTHER